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ABSTRACT
Introduction: Optimal antithrombotic therapy
after transcatheter aortic valve replacement
(TAVR) remains unclear. We evaluated the
association between antithrombotic regimens
and outcomes in TAVR patients.
Methods: We retrospectively analyzed consec-
utive patients who underwent TAVR at a single
academic center from April 2009 to March
2014. Antithrombotic regimens were classified
as single or dual antiplatelet therapy (AP), single
antiplatelet plus anticoagulant (SAC), or triple
therapy (TT). The primary endpoint was a
composite of death, myocardial infarction (MI),
stroke, and major bleeding. Adjusted hazard
ratios (HRs) were obtained with best subset
variable selection methods using bootstrap
resampling.
Results: Of 246 patients who underwent TAVR,
241 were eligible for analysis with 133, 88, and
20 patients in the AP, SAC, and TT groups,
respectively. During a median 2.1-year follow-
up, 53.5% had at least one endpoint—the most
common was death (68%), followed by major
bleeding (23%), stroke (6%), and MI (3%). At
2 years, the composite outcome occurred in
70% of TT, 42% of SAC, and 31% of AP patients.
Compared to AP, adjusted HRs for the com-
posite outcome were 2.88 [95% Confidence
intervals (CI) (1.61–5.16); p = 0.0004] and 1.66
(95% CI [1.13-2.42]; p = 0.009) in the TT and
SAC groups, respectively. Mortality rates at
2 years were 61% in the TT, 32% in the SAC,
and 26% in the AP groups (p = 0.005).
Conclusions: The risk of the composite out-
come of death, MI, stroke, or major bleeding at
2-year follow-up was significantly higher in
TAVR patients treated with TT or SAC versus AP,
even after multivariate adjustment.
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INTRODUCTION
Transcatheter aortic valve replacement (TAVR)
has become an established treatment for
patients with symptomatic, severe aortic
stenosis with intermediate, high, or prohibitive
surgical risk [1–5]. Despite advances in patient
selection, operator experience, and valve deliv-
ery systems, ischemic and bleeding complica-
tions remain important concerns after TAVR, as
they are associated with increased morbidity
and mortality [6–8]. However, limited data are
available comparing long-term outcomes with
varying antithrombotic regimens after TAVR.
Current guidelines recommend dual anti-
platelet therapy with aspirin (indefinitely) and
clopidogrel (for 1–6 months) after TAVR in
patients with no indication for therapeutic oral
anticoagulation (OAC). In patients with an
indication for OAC, guidelines generally rec-
ommend against the use of triple therapy
[9–12]. However, these recommendations have
been made empirically and vary amongst pro-
fessional societies, leading to heterogeneity in
clinical practice [13].
We sought to examine the association
between different antithrombotic regimens and
the risk of mortality, ischemic, and bleeding
outcomes in a non-selected clinical population
undergoing TAVR. Specifically, we compared
outcomes among TAVR patients prescribed
single or dual antiplatelet therapy (AP), a single
antiplatelet agent plus OAC (SAC), or triple
therapy (TT) with dual antiplatelet therapy
(DAPT) and OAC.
METHODS
Study Population
We retrospectively analyzed consecutive
patients who underwent TAVR at Brigham and
Women’s Hospital in Boston, Massachusetts,
from April 2009 through March 2014. Baseline
medical history, routine laboratory testing,
electrocardiography, echocardiography,
CHA2DS2-VASc score, ATRIA score, New York
Heart Association functional classification, pre-
procedure antithrombotic regimen, and TAVR
procedural characteristics were collected.
Patients were then prospectively followed for
ascertainment of study outcomes. The Institu-
tional Review Board of Partners Healthcare in
Boston, Massachusetts, approved the study, and
signed informed consent was obtained from
each patient. All procedures performed in
studies involving human participants were in
accordance with the 1964 Helsinki Declaration
and its later amendments or comparable ethical
standards.
Antithrombotic Regimen
The antithrombotic regimen was noted pre-
TAVR, at the time of discharge from TAVR
admission, at 30 days, at 1 year, and through
April 2016 using electronic health records and
telephone follow-up. Antithrombotic regimens
were classified as single or dual antiplatelet
therapy only (AP), single antiplatelet plus anti-
coagulant therapy (SAC), or triple therapy (TT)
with DAPT plus OAC. Patients were grouped
according to the antithrombotic regimen at the
time of latest follow-up for the purposes of the
statistical analysis.
Outcomes
The primary endpoint was the composite of
death, myocardial infarction (MI), stroke, or
major bleeding (requiring hospitalization, life-
threatening, or fatal). Outcomes were assessed
according to Valve Academic Research Consor-
tium-2 definitions [14] at discharge, 30 days,
1 year, and through April 2016 using electronic
medical record data and telephone follow-up
with a standardized questionnaire.
Statistical Analysis
To determine associations between antithrom-
botic therapy group and the primary composite
outcome, a Cox proportional hazards model
was used. A multivariable model was developed
with best subset variable selection methods
using bootstrap resampling in order to account
for model variation due to small sample size
[15]. The final model included adjustment for
72 Cardiol Ther (2018) 7:71–77
chronic lung disease, prior percutaneous coro-
nary intervention (PCI), male sex, age, and low-
gradient aortic stenosis (defined as left ventric-
ular ejection fraction\ 50%, aortic valve
area\1.0 cm2, and mean aortic valve gradi-
ent\40 mmHg). Results are reported as adjus-
ted hazard ratios (HR) and 95% confidence
intervals (CI). Proportional hazards assumption
for the final model was assessed by score tests
using scaled Schoenfeld residuals. Crude
cumulative event rates were calculated by the
complement of Kaplan–Meier survival esti-
mates, and log-rank test p values are also
reported. All reported p values are two-sided,
and significance level was set at alpha 0.05.
Analyses were performed using SAS version 9.4
(SAS Institute Inc., Cary, NC, USA).
RESULTS
Table 1 outlines the baseline characteristics of
each study group. A total of 246 patients
underwent TAVR from April 2009 to March
2014. Of these, five patients were excluded for
the following reasons: prescribed no
antithrombotic therapy (n = 2) and incomplete
post-discharge follow-up (n = 3), leaving 241
patients for final analysis. The baseline charac-
teristics among the AP (n = 133), SAC (n = 88),
and TT (n = 20) groups were similar, with the
exception of rates of atrial fibrillation or flutter
(p\ 0.01), indication for OAC (p\ 0.01), aortic
valve mean gradient (p = 0.044), and aortic
valve peak velocity (p = 0.047) (Table 1). Over-
all, 67.2% of cases were done with a trans-
femoral approach, while 16.2% and 15.8% of
cases were performed via a transapical and
transaortic approach, respectively.
Of the 241 patients followed for a median of
2.1 years (interquartile range, 0.7–2.9 years),
53.5% (n = 129) had at least one endpoint. The
components of the composite outcome in the
cohort were distributed as death (68%), major
bleeding (23%), stroke (6%), and MI (3%) at
2-year follow-up. The risk of the composite
outcome was highest with TT (70%; HR 2.88,
95% CI 1.61–5.16, p = 0.0004) and intermediate
with SAC (42%; HR 1.66, 95% CI 1.13–2.42,
p = 0.009), compared to AP (31%) at 2 years
(Fig. 1). Mortality rates at 2 years were 61%,
32%, and 26% (p = 0.005) in the TT, SAC, and
AP groups, respectively, while major bleeding
rates were 29%, 18%, and 9.1%, respectively
(p = 0.02). Rates of stroke and MI were low and
similar among groups.
A total of 132 patients in the cohort had an
indication for OAC (88.6% had atrial fibrillation
or flutter), including 40 in the AP group, 76 in
the SAC group, and 16 in the TT group. Among
patients with an indication for OAC, the com-
posite outcome occurred in 69% of TT, 38% of
SAC, and 38% of AP patients (p = 0.06) at 2-year
follow-up.
DISCUSSION
This study evaluated the association between
post-TAVR antithrombotic regimen and the
composite outcome of death, MI, stroke, or
major bleeding in a single-center cohort of 241
consecutive patients with at least 2-year follow-
up. Patients treated with TT or SAC versus AP
had a higher incidence of the composite out-
come, even after multivariate adjustment. This
finding was driven by an increase in both mor-
tality and major bleeding in the TT and SAC
groups.
TAVR patients are at high risk for both
ischemic and bleeding events by virtue of co-
morbidities and the procedure itself. Both types
of complications are associated with increased
morbidity and mortality. Moreover, TAVR
patients frequently undergo pre-emptive coro-
nary artery stenting, which necessitates DAPT,
and approximately half have atrial fibrillation
requiring OAC. Given this complex interplay,
identifying an antithrombotic regimen that
achieves an optimal balance between ischemic
protection and bleeding risk mitigation is
paramount in this patient population. Never-
theless, guideline recommendations for
antithrombotic therapy after TAVR remain
empiric, and are extrapolated from the PCI
experience and early TAVR clinical trial proto-
cols [16].
Our analysis indicates that treatment with
TT or SAC is associated with adverse clinical
outcomes compared to treatment with AP alone
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Table 1 Patient characteristics by study group
AP (n = 133) SAC (n = 88) TT (n = 20) Overall (n = 241) p value
Age (years) 80.9 ± 10.0 81.0 ± 7.9 80.9 ± 6.3 80.9 ± 9.0 0.68
Male sex, n (%) 63 (47.4) 53 (60.2) 12 (60) 128 (53.1) 0.14
BMI (kg/m2) 26.6 ± 7.4 28.2 ± 5.9 28.1 ± 5.3 27.3 ± 6.8 0.053
Atrial ﬁbrillation or ﬂutter, n (%) 31 (23.3) 72 (81.8) 14 (70) 117 (48.5) \0.001
Prior DVT/PE, n (%) 9 (6.8) 11 (12.5) 2 (10) 22 (9.1) 0.35
CHA2DS2-VASc score 5.2 ± 1.3 5.5 ± 1.2 5.7 ± 1.1 5.4 ± 1.3 0.10
ATRIA score 2.7 ± 1.0 2.7 ± 0.8 3.1 ± 0.8 2.7 ± 0.9 0.20
Indication for OAC, n (%) 40 (30.1) 76 (86.4) 16 (80) 132 (54.8) \0.001
Prior GI bleeding, n (%) 23 (17.3) 9 (10.2) 4 (20) 36 (14.9) 0.28
Dyslipidemia, n (%) 105 (78.9) 72 (81.8) 20 (100) 197 (81.7) 0.076
Hypertension, n (%) 117 (88) 81 (92) 20 (100) 218 (90.5) 0.19
Diabetes mellitus, n (%) 52 (39.1) 37 (42) 7 (35) 96 (39.8) 0.82
Prior PCI, n (%) 37 (27.8) 25 (28.4) 9 (45) 71 (29.5) 0.28
Peripheral arterial disease, n (%) 30 (22.6) 19 (21.6) 6 (30) 55 (22.8) 0.72
Cerebrovascular disease, n (%) 14 (10.5) 16 (18.2) 4 (20) 34 (14.1) 0.20
Chronic lung disease, n (%) 49 (36.8) 41 (46.6) 8 (40) 98 (40.7) 0.35
On hemodialysis, n (%) 5 (3.8) 2 (2.3) 1 (5) 8 (3.3) 0.76
NYHA class, n (%) 0.86
I 0 (0) 1 (1.2) 0 (0) 1 (0.4)
II 7 (5.7) 5 (5.9) 2 (10.5) 14 (6.2)
III 82 (66.7) 55 (64.7) 11 (57.9) 148 (65.2)
IV 34 (27.6) 24 (28.2) 6 (31.6) 64 (28.2)
LVEF (%) 52.9 ± 15.0 54.4 ± 14.2 55.3 ± 16.8 53.7 ± 14.8 0.60
Aortic valve area (cm2) 0.6 ± 0.2 0.7 ± 0.2 0.7 ± 0.1 0.7 ± 0.2 0.65
Aortic valve mean gradient (mmHg) 47.0 ± 13.8 41.7 ± 12.3 43.1 ± 15.6 44.8 ± 13.6 0.045
Aortic valve peak velocity (m/s) 4.4 ± 0.6 4.2 ± 0.6 4.3 ± 0.8 4.3 ± 0.6 0.047
Low gradient ASa, n (%) 24 (18) 11 (12.5) 2 (10) 37 (15.4) 0.42
Moderate or severe MR, n (%) 47 (38.5) 33 (38.4) 7 (36.8) 87 (38.3) 0.99
Valve sheath access site n (%) 0.41
Transfemoral 93 (69.9) 56 (63.6) 13 (65) 162 (67.2)
Transapical 15 (11.3) 20 (22.7) 4 (20) 39 (16.2)
Transaortic 24 (18) 11 (12.5) 3 (15) 38 (15.8)
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after TAVR, which is consistent with findings
from other studies of patients undergoing TAVR
[17, 18] and surgical aortic valve replacement
[19]. We did not observe a benefit on ischemic
endpoints with regimens using 2 or 3
antithrombotics compared to AP alone, as rates
of MI and stroke were similar among the three
treatment groups, but the study was not pow-
ered to do so. In addition to higher rates of
bleeding with TT and SAC, we observed a higher
mortality rate with these treatment strategies
compared to AP. Importantly, our analysis
shows that these effects persisted over a period
of 2 years. However, while bleeding is reduced
when fewer antithrombotic agents are used,
omitting an anticoagulant in patients with
atrial fibrillation (or another indication for
OAC) significantly increases the risk of throm-
boembolism, which often has more serious
clinical consequences than bleeding.
The relatively low number of patients, espe-
cially in the TT group, is an important limita-
tion of our study. Additionally, patients in the
TT and SAC groups had higher rates of atrial
fibrillation/flutter and an indication for OAC,
which could have led to confounding by indi-
cation despite our use bootstrap resampling.
Patients were categorized based on antithrom-
botic regimen at the latest time of follow-up,
and results could differ if an intention-to-treat
analysis was carried out. The patients we studied
represent a high-risk cohort, as evidenced by
the large burden of co-morbidities and high
2-year mortality rate. Thus, our results may not
be applicable to lower-risk patients. Lastly, our
study is observational in nature, and random-
ized trials are needed to determine the optimal
antithrombotic regimen after TAVR in patients
with and without an indication for anticoagu-
lation. The recently reported aspirin versus
aspirin ? clopidogrel following transcatheter
aortic valve implantation (ARTE) trial demon-
strated that aspirin monotherapy reduced risk
of bleeding, without increasing the risk of MI or
stroke, compared to DAPT in TAVR patients
[20]. Ongoing trials include ATLANTIS
(NCT02664649), AUREA (NCT01642134), AVA-
TAR (NCT02735902), ENVISAGE-TAVR
(NCT02943785), GALILEO (NCT02556203),
POPular-TAVI (NCT02247128), and TICTAVR
(NCT02817789). The results of these trials will
Table 1 continued
AP (n = 133) SAC (n = 88) TT (n = 20) Overall (n = 241) p value
Other 1 (0.8) 1 (1.1) 0 (0) 2 (0.8)
Continuous variables are presented as mean ± standard deviation
AP antiplatelet therapy, SAC single antiplatelet plus oral anticoagulant therapy, TT triple therapy, BMI body mass index,
DVT deep venous thrombosis, PE pulmonary embolism, ATRIA anticoagulation and risk factors in atrial ﬁbrillation, OAC
oral anticoagulation, GI gastrointestinal, PCI percutaneous coronary intervention, NYHA New York Heart Association,
LVEF left ventricular ejection fraction, AS aortic stenosis, MR mitral regurgitation
a Deﬁned as aortic valve mean gradient\ 40 mmHg, left ventricular ejection fraction\ 50%, and aortic valve
area\ 1 cm2
Fig. 1 Kaplan–Meier time-to-event curves for the primary
composite endpoint of death, myocardial infarction,
stroke, or major bleeding stratiﬁed by treatment group.
TAVR transcatheter aortic valve replacement, HR hazard
ratio, CI conﬁdence interval, AP antiplatelet therapy, SAC
single antiplatelet plus anticoagulant therapy, TT triple
therapy
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likely inform future guidelines and clinical
decision-making.
CONCLUSIONS
In a consecutive series of patients from our
institution undergoing TAVR between 2009 and
2014, treatment with triple therapy or a single
antiplatelet agent plus an oral anticoagulant
was associated with an increased risk of the
composite of death, MI, stroke, or major
bleeding at 2 years compared to treatment with
antiplatelet therapy alone, even after multi-
variable adjustment. Further prospective inves-
tigations to determine the optimal
antithrombotic regimen in TAVR patients are
awaited.
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